ArticleClinical reviews in allergy & immunology2016
The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.
Article in Clinical reviews in allergy & immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis.Gut · 2025Guideline
- Impact of Type 2 Diabetes Mellitus on Liver Fibrosis and Hepatic Steatosis in Patients with Primary Biliary Cholangitis: A Longitudinal Study.Digestive diseases and sciences · 2026Article
- Multi-omics analysis reveals gut microbiota-metabolite interactions and their association with liver function in autoimmune overlap syndrome.World journal of gastroenterology · 2025Article
- Overlap syndromes in autoimmune liver disease: a review.Translational gastroenterology and hepatology · 2025Review
- Predictors of survival in autoimmune liver disease overlap syndromes.World journal of hepatology · 2024Article
- Primary Biliary Cholangitis (PBC)-Autoimmune Hepatitis (AIH) Variant Syndrome: Clinical Features, Response to Therapy and Long-Term Outcome.Journal of clinical medicine · 2023Article
- Clinical significance of serum antinuclear antibodies in patients with autoimmune hepatitis and comorbidity.Clinical and experimental medicine · 2023Article
- Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021).Journal of clinical and translational hepatology · 2023Article
- Regulatory T-cell deficiency leads to features of autoimmune liver disease overlap syndrome in scurfy mice.Frontiers in immunology · 2023Article
- Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China.World journal of gastroenterology · 2022Article
- APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.Hepatology international · 2022Article
- [Guidelines on the diagnosis and management of primary biliary cholangitis (2021)].Zhonghua nei ke za zhi · 2021Article
- Characteristics and Inpatient Outcomes of Primary Biliary Cholangitis and Autoimmune Hepatitis Overlap Syndrome.Journal of clinical and translational hepatology · 2021Article
- Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis.Pathologica · 2021Review
- Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study.Canadian journal of gastroenterology & hepatology · 2021Article
- Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2020Review
- Dysregulation of Circulating FGF19 and Bile Acids in Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome.BioMed research international · 2020Article
- Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans.Archives of medical science : AMS · 2018Article
- The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review.Clinical reviews in allergy & immunology · 2018Review
- Autoimmune Hepatitis in the Asia-Pacific Area.Journal of clinical and translational hepatology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although a variant of primary biliary cirrhosis (PBC) characterized by features of autoimmune hepatitis (AIH) has been recognized for many years, few studies with ample numbers of patients have focused on its natural history. This study aimed to clarify the natural history, prognosis, and response to therapy in a cohort of patients with PBC with AIH features. We retrospectively analyzed 277 PBC patients without AIH features and 46 PBC patients with AIH features seen between September 2004 and April 2014. The 5-year adverse outcome-free survival of PBC patients with AIH features was 58% compared to 81% in PBC patients without AIH features. Multivariate analysis in the patients with AIH features indicated that total bilirubin ≥ 2.70× the upper limit of normal predicted a poor prognosis (p = 0.008, relative risk 8.39, 95% confidence interval (CI) 1.73, 40.73). Combination therapy with ursodeoxycholic acid (UDCA) and immunosuppression provided better short-term responses in PBC patients with AIH features, defined by multiple criteria. Higher aspartate aminotransferase (AST) level at accession suggested better prognosis for PBC patients with AIH features while worse prognosis for PBC patients without AIH features. PBC patients with AIH features differ from those without AIH features in terms of natural history, prognostic indicators, and response to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.